Men with end-stage kidney disease and prostate cancer (PCa) are not more likely to die from the malignancy if they receive a kidney transplant (KT) compared with undergoing dialysis, data presented at the virtual 2021 American Transplant Congress suggest.
Using Surveillance, Epidemiology and End Results (SEER)-Medicare registry 2004-2015 data, Nagaraju Sarabu, MD, of University Hospital Cleveland Medical Center in Cleveland, Ohio, and colleagues conducted a retrospective study of 1959 men diagnosed with PCa following a diagnosis of end-stage kidney disease: 1478 on dialysis and 481 with a functioning kidney transplant.
In adjusted analyses, KT recipients had a significant 45% reduced risk for overall mortality compared with dialysis patients, but the groups did not differ significantly with regard to PCa-specific mortality, Dr Sarabu’s team reported.
Read full article, here.